Actimed Aims High With Cancer Cachexia Prospect
FDA Okays Late-Stage Program
The UK firm has got the green light in the US to conduct two Phase IIb/III trials of its cancer cachexia candidate S-pindolol but a lot more money needs to be raised to complete them.
You may also be interested in...
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.